CPIX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
2.2M
+1195.4%
166.5K
-98.2%
9.1M
-33.2%
13.7M
+7861.0%
171.8K
Cost of Revenue
1.1M
0
-100.0%
1.9M
-13.7%
2.2M
0
Gross Profit
1.1M
+557.3%
166.5K
-97.7%
7.2M
-37.1%
11.4M
+6556.5%
171.8K
Operating Expenses
3.0M
-8.9%
3.3M
-67.8%
10.3M
-19.4%
12.8M
+323.0%
3.0M
R&D
841.2K
+8.9%
772.2K
-47.1%
1.5M
-5.9%
1.5M
+139.7%
646.5K
SG&A
2.2M
-14.3%
2.5M
-66.6%
7.6M
-25.6%
10.2M
+331.2%
2.4M
Operating Income
-1936482
+38.7%
-3160461
-1.0%
-3129292
-128.2%
-1371202
+52.0%
-2856522
EBITDA
-1906178
+56.3%
-4365125
-135.6%
-1853009
-462.7%
-329307
+88.4%
-2834967
Net Income
77.8M
+1919.6%
-4274430
-30.0%
-3287051
-130.1%
-1428642
+26.7%
-1949046
EPS (Basic)
$5.19
+1889.7%
$-0.29
-31.8%
$-0.22
-120.0%
$-0.10
+23.1%
$-0.13
EPS (Diluted)
$5.07
+1848.3%
$-0.29
-31.8%
$-0.22
-120.0%
$-0.10
+23.1%
$-0.13
Shares (Diluted)
15.3M
+2.4%
15.0M
+0.1%
15.0M
+5.1%
14.2M
-4.8%
15.0M
Cumberland Pharmaceuticals (CPIX) — Financials